Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

21.12 +0.18 (+0.86%)
Streaming Delayed Price Updated: 10:41 AM EDT, Oct 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about ACADIA Pharmaceuticals Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
This ACADIA Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
 
Via Benzinga
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Fits the 'Affordable Growth' Investment Framework
ACADIA Pharmaceuticals offers strong growth and profitability at a reasonable industry valuation, making it a prime candidate for affordable growth investors. 
Via Chartmill
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Shows Strong Growth and Positive Technical Setup
ACADIA Pharmaceuticals shows strong EPS and revenue growth with a positive technical setup, making it a compelling growth stock candidate. 
Via Chartmill
Leap Therapeutics (LPTX) Plummets Over 20% Amidst Profit-Taking and Volatility Ahead of Key Clinical Data
Boston, MA – October 3, 2025 – Leap Therapeutics, Inc. (NASDAQ: LPTX) experienced a sharp downturn in its stock performance today, with shares falling by over 20% in intraday trading. This significant... 
Via MarketMinute
Earnings Scheduled For August 6, 2025
 
Via Benzinga
The Analyst Verdict: ACADIA Pharmaceuticals In The Eyes Of 11 Experts
 
Via Benzinga
Beyond The Numbers: 11 Analysts Discuss ACADIA Pharmaceuticals Stock
In the preceding three months, 11 analysts have released ratings for ACADIA Pharmaceuticals (NASDAQ: ACAD), presenting a wide array of perspectives from bullish to bearish. 
Via Benzinga
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Presents an Affordable Growth Opportunity
Discover ACADIA PHARMACEUTICALS (ACAD), a strong affordable growth stock with impressive earnings, solid financials, and a reasonable valuation in the biotech sector. 
Via Chartmill
Acadia Pharma Faces Trial Setback As Prader-Willi Syndrome Trial Falls Short
Acadia's Phase 3 Compass Prader-Willi syndrome trial failed to meet endpoints, but the company projects $1 billion in sales in 2025 and highlights a strong pipeline outlook. 
Via Benzinga
Acadia Pharma Tumbles On Failed Appetite Suppressant; Soleno Surges
The companies are working on treatments for a rare, genetic disease that can cause excessive hunger. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Acadia Pharmaceuticals’ Investigational Drug For Rare Genetic Disorder Fails In Late-Stage Study
The company noted that the safety and tolerability of intranasal Carbetocin were consistent with those observed in previous clinical trials. 
Via Stocktwits
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Shows Strong Technical Setup for Potential Breakout
ACADIA Pharmaceuticals (ACAD) shows strong technical momentum with a high-quality consolidation pattern, signaling a potential breakout opportunity for traders. 
Via Chartmill
Assessing ACADIA Pharmaceuticals: Insights From 12 Financial Analysts
 
Via Benzinga
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Emerges as a Top Affordable Growth Stock
ACADIA Pharmaceuticals (ACAD) offers strong growth metrics and a reasonable valuation within the biotech sector, making it a top affordable growth stock pick. 
Via Chartmill
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) – A Strong Affordable Growth Stock with Fair Valuation and High Potential
ACADIA Pharmaceuticals (ACAD) offers strong growth, fair valuation, and solid financial health, making it a top pick for the Affordable Growth investment strategy. 
Via Chartmill
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Combines Strong Fundamentals with Bullish Technicals for Growth Potential
ACADIA Pharmaceuticals (ACAD) shows strong growth fundamentals with rising revenue, EPS, and solid margins, plus a bullish technical breakout, making it a promising stock pick. 
Via Chartmill
Acadia (ACAD) Q2 Revenue Rises 9%
Via The Motley Fool
Topics Intellectual Property
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Q2 2025 Earnings: Revenue Growth Meets Expectations, EPS Beats Estimates
Acadia Pharmaceuticals reports Q2 2025 earnings with $264.6M revenue (+9% YoY), EPS beats at $0.16. NUPLAZID & DAYBUE sales grow, reaffirms full-year guidance. Stock up 12.5% in past month. 
Via Chartmill
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) – A High-Growth Biotech Stock with Fair Valuation
ACADIA Pharmaceuticals (ACAD) offers strong growth, solid profitability, and fair valuation, making it a top pick for investors seeking affordable growth in biotech. 
Via Chartmill
What Analysts Are Saying About ACADIA Pharmaceuticals Stock
 
Via Benzinga
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) – A Strong Growth Stock with Technical Breakout Potential
ACADIA PHARMACEUTICALS (NASDAQ:ACAD) shows strong growth fundamentals and a bullish technical setup, making it a noteworthy stock for growth investors. 
Via Chartmill
Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity
Acadia Pharmaceuticals is working on its next-generation Nuplazid and, for CEO Catherine Owen Adams, the journey is personal. 
Via Investor's Business Daily
Topics Intellectual Property
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) - A Promising Growth Stock at a Reasonable Valuation
ACADIA PHARMACEUTICALS (NASDAQ:ACAD) offers strong growth potential with reasonable valuation, solid financial health, and improving profitability, making it a compelling candidate for growth... 
Via Chartmill
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) – A Strong Growth Stock with Technical Breakout Potential
ACADIA PHARMACEUTICALS (NASDAQ:ACAD) shows strong growth fundamentals and a bullish technical setup, making it a stock to watch for potential breakout opportunities. 
Via Chartmill
13 Analysts Assess ACADIA Pharmaceuticals: What You Need To Know
 
Via Benzinga
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) - A Promising Affordable Growth Stock
ACADIA PHARMACEUTICALS (NASDAQ:ACAD) offers strong growth potential with reasonable valuation, solid financial health, and improving profitability, making it an interesting candidate for growth... 
Via Chartmill
JPMorgan Lifts Acadia Price Target After Nuplazid Patent Victory
Acadia wins Nuplazid patent case, extending protection to 2038, as JP Morgan boosts price target ahead of key appeal on the ‘740 COM patent. 
Via Benzinga
Topics Intellectual Property
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) - A Promising Growth Stock at a Reasonable Valuation
ACADIA PHARMACEUTICALS (NASDAQ:ACAD) offers strong growth potential with reasonable valuation, solid financial health, and improving profitability, making it an interesting stock for growth investors. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.